New COVID-19 Pill Reduces Risk of Death & Hospitalization by 50%, According to Study

An experimental coronavirus treatment pill is making headlines on Friday (October 1).

The oral drug, called molnupiravir, is being developed by Merck & Co Inc. and Ridgeback Biotherapeutics LP, and reduced hospitalization and death by around 50% according to clinical trial results, via Reuters.

Click inside to read more…

The companies plan to seek U.S. emergency use authorization for the pill as soon as possible, as well as worldwide. If it is authorized, it will be the first oral antiviral medication for COVID-19.

“This is going to change the dialogue around how to manage COVID-19,” said Merck’s Robert Davis to Reuters.

An analysis of 775 patients in the study found 7.3% of participants that took molnupiravir were either hospitalized or had died by 29 days after treatment, compared with 14.1% of placebo patients. There were no deaths in the molnupiravir group, and eight deaths of placebo patients.

One airline is currently getting media attention for firing hundreds of employees for not taking the vaccine.

from Just Jared https://ift.tt/3ioM7KZ